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ABSTRACT 
Disorders of calcium homeostasis are uncommon but important because of the broad 
spectrum of potential underlying causes that lie on a spectrum from the benign to the life-
threatening. Paediatricians may find them challenging because they do not arise often 
enough for the investigative approach to be second nature. We report a 4 year old with acute 
onset profound hypercalcaemia. We focus on an approach to the clinical problem that is 
based on the potential organ systems affected, namely the gut, bone and kidney. Key 
biochemical parameters that may help the paediatric team to reach a diagnosis are 
discussed as well as important components of acute management. 
INTRODUCTION 
David, a 4 ½ year old boy, was transferred to the regional children’s hospital with a 
four day history of fever, lethargy, and vomiting.  He was constipated, passing urine 
frequently and complained of sore eyes. He had no past medical or family history of 
note, and was developmentally normal.  His only hospital admission had been for a 
left ankle fracture two years previously.  On examination he was unwell, lethargic, and 
pale with conjunctival redness. He was mildly dehydrated with dry mucosal 
membranes and an elevated heart rate (128/min).  There were no dysmorphic features, 
no organomegaly and no obvious skeletal malformation or tenderness.  
Initial investigations revealed profound hypercalcaemia – total calcium of 5.07mmol/l 
and an ionised calcium of 2.76mmol/l.  He was hypokalaemic (2.8mmol/l), with 
borderline hypernatraemia (145mmol/l) and had an elevated creatinine at 68μmol/l 
(normal range up to 37μmol/l).  Phosphate was 1.93mmol/l (0.9-1.8mmol/l), alkaline 
phosphatase was 185 U/l (150-375U/l). Magnesium and thyroid function were normal. 
Calcium concentrations were repeated but were again markedly elevated.  Full blood 
count showed normal haemoglobin and platelets, but elevated white count (22.1x109/l 
of which 19.07 x109/l were neutrophils).  A blood film was unremarkable.  Urinalysis 
demonstrated no glycosuria, but an elevated calcium:creatinine ratio of 6.13mol/mol 
(normally less than 0.7mmol/mmol)[1]. 
COMMENT – Acute hypercalcaemia: Symptoms 
The well-known adage of ‘bones, stones, moans, and groans’ is still relevant in paediatric 
practice.  Symptoms of hypercalcaemia often include abdominal and bone pain, with nausea 
and vomiting.  The associated polyuria can lead to significant dehydration and shock.  
Persistent chronic hypercalcaemia leads to signs such as conjunctivitis in addition to 
nephrocalcinosis, renal calculi, renal impairment and peripheral vascular calcification which 
can have major implications for cardiovascular health later in life.  Psychiatric illness can be 
a feature of paediatric hypercalcaemia but the incidence is poorly defined. 
Acute hypercalcaemia: Initial investigations 
Hypercalcaemia is uncommon in the young child, profound hypercalcaemia like this even 
more so. It was important to confirm that calcium concentrations were abnormal whilst 
instigating investigations that might help the diagnostic process. Where there is such a 
significant abnormality in serum electrolytes, emergency management is the main priority.  In 
hypercalcaemic patients it is important to consider the age of the patient and the principle 
factors that regulate calcium concentrations, notably parathyroid hormone (PTH) and vitamin 
D (Table 1).  Vitamin D metabolism is intrinsically linked to that of calcium. Dietary vitamin D 
is hydroxylated to 25 hydroxyvitamin D – 25(OH)D, then further hydroxylated by the kidney 
to 1,25 dihydroxyvitamin D – 1,25(OH)D (by the enzyme 1-alpha hydroxylase) – or 
inactivated by the liver to 24,25 (OH)D.  With modern analysers a PTH value may be 
obtained outside normal working hours.  This is helpful because the presence of low, normal 
or high PTH values will point the clinician in very different directions when considering the 
underlying differential diagnosis and pertinent investigations. Saving serum that may be 
used at a later date is useful in a situation like this. 
Table 1 
Key hormonal regulators of serum calcium and their actions 
   
 
Regulator Actions 
PTH Increases bone reabsorption by osteoclasts*  
Increases renal absorption of filtered calcium  
Stimulates conversion of 25(OH)D to 1,25(OH)D (activated vitamin D, also 
called calcitriol) 
1,25(OH)D Increases bone reabsorption by osteoclasts  
Increases renal tubular reabsorption of filtered calcium  
Increases intestinal absorption of calcium via active transport 
Calcitonin 
(thought to be 
of little 
physiological 
significance 
beyond the 
neonatal 
period 
Inihibits bone reabsorption by osteoclasts  
Reduces renal absorption of filtered calcium  
Decreases intestinal absorption of calcium 
* - the mechanisms of PTH on bone metabolism are complex; here we provide a simplified 
overview. 
Acute hypercalcaemia: Management 
The acute management of hypercalcaemia centres on enhancing physiological calcium 
excretion where possible. 
1- Intravenous fluids 
Under normal circumstances, filtered calcium is predominantly passively reabsorbed 
together with sodium in the proximal tubule (Fig 1A) although a fraction (10-15%) of calcium 
is later actively reabsorbed within the distal convoluted tubule.  Sodium is also reabsorbed 
via the Na-K-2Cl channel and potassium is later returned to the urine via the renal outer 
medullary potassium (ROMK) channel to maintain the diffusion gradient.   
Hypercalcaemia impacts on sodium (and thus water) reabsorption leading to a diuresis.  This 
may be caused by either the greater ionic charge of calcium compromising the NaK2CL 
channel or an inherent increased osmotic effect of calcium within the urine.  The higher 
positive charge of calcium also inhibits potassium transfer via ROMK back into the urine in 
the proximal tubule.  To maintain normovolaemia, sodium is then preferentially reabsorbed 
later in the tubule in exchange for potassium leading to hypokalaemia.   
Volume expansion enhances renal calcium excretion.  Expanding intravascular volume with 
saline reduces initial sodium reabsorption, so less calcium is passively reabsorbed and less 
potassium is lost through distal exchange (Fig 1B).  Hyperhydration with 3l/m2/24 hours of 
0.9% saline can significantly improve calcium excretion and is particularly useful if the child 
is already volume depleted. 
2- Loop diuretics 
If the child is well-hydrated calcium excretion can be further increased via the administration 
of a loop diuretic, such as furosemide.  Loop diuretics block the Na-K-2Cl co-transporter in 
the thick ascending limb of the loop of Henle.  Blocking sodium reabsorption again reduces 
the concurrent calcium reabsorption that occurs passively, but will exacerbate hypokalaemia.   
This effectively mimics the normal physiological response to high serum calcium, which is 
why diuretics should be used with care, as intravascular depletion will lead to exacerbation 
of the hypercalcaemia.   
3- Dialysis 
In cases where severe hypercalcaemia is associated with oliguric renal impairment, acute 
haemodialysis may be needed to rapidly remove calcium. 
David received intravenous fluids but total calcium levels rose to 5.55mmol/l.  The 
renal impairment resolved, but his hypokalaemia worsened (K+ of 2.1mmol/l).  Whilst 
David was being treated and whilst PTH and Vitamin D levels were awaited, the 
differential diagnosis was considered in greater detail.  
David had been staying with his grandparents in a caravan in the days leading up to 
his presentation. One of the grandparents was on a flavoured combined vitamin 
D/calcium preparation, but the family did not feel that accidental ingestion was likely.   
 
COMMENT – Causes of hypercalcaemia  
Hypercalcaemia can be categorised in a number of ways, for example– by age (infancy or 
beyond), or according to the presence of normal/elevated or low PTH levels. The latter 
approach has recently been reviewed in this journal, with a thorough discussion of the 
pathophysiological mechanisms behind various causes of hypercalcaemia[2].  Here, we 
have opted to focus on mechanism and whether elevated blood calcium concentrations can 
be primarily linked to pathology in the gut, bone or kidney. Specifically, altered calcium 
concentrations may reflect dietary absorption in the gastro-intestinal tract (GUT), altered 
storage/release from the skeleton (BONE), or altered renal handling (KIDNEY) – Table 2.  In 
many instances the hypercalcaemia will reflect alterations in more than one of these organ 
systems although here we will consider each mechanism separately for the sake of clarity. 
Table 2 
Causes of hypercalcaemia by mechanism 
Excess vitamin D intake or 
generation with increased 
gut absorption 
Abnormal bone turnover Impaired renal clearance 
Excess exogenous Vit D Malignancy Familial hypocalciuric  
hypercalcaemia (FHH) 
Idiopathic hypercalcaemia of 
infancy /CYP24A1 mutation 
Hypophosphatasia Chronic renal impairment 
Hyperparathyroidism Hyperparathyroidism Hyperparathyroidism 
Willliams syndrome  Bartters’ syndrome 
Subcutaneous fat necrosis   
Granulomatous disease   
 
Differential diagnosis of hypercalcaemia – GUT absorption 
Accidental ingestion is a key consideration in a clinical picture like this and it was important 
to establish whether there was any possibility of David consuming excessive quantities of 
calcium or vitamin D which will enhance calcium absorption from the gut. These preparations 
are likely to be more widespread in homes and drug cabinets today than they were in the 
past. The deliberate flavouring of many of these medicines to make them more palatable 
may increase the risk of accidental overdosage.   
Preparations of vitamin D may be ‘inactive’ i.e. requiring hydroxylation by the liver (25-
hydroxylation) and the kidney (1-hydroxylation), or they may be ‘active’ preparations already, 
such as calcitriol (1,25(OH)D).  Excessive ingestion of inactive vitamin D preparations such 
as ergocalciferol may not cause any clinical sequelae[3].  There are likely to be inter-
individual differences in susceptibility to hypercalcaemia. 
The minimal dose of Vitamin D that may cause harm remains contentious, though is 
probably at least 10,000 units daily[4].   There is inter-individual variability in sensitivity to 
exogenous vitamin D which reflect differences in vitamin D metabolism and tissue sensitivity. 
This was highlighted by the development of infant hypercalcaemia following vitamin D 
supplementation of formula milk in the UK in some individuals but not everyone. This may in 
part reflect CYP24A1 gene activity (the gene that encodes the enzyme involved in 
1,25(OH)D degradation) with affected children being less able to regulate their level of 
activated vitamin D[5].  The pharmacokinetics of vitamin D, with rising concentrations up to a 
month post-ingestion is a further key consideration[6].    
Vitamin D levels may also be raised due to excessive endogenous vitamin D generation – 
this will be discussed later.   
Total vitamin D and PTH concentrations were available within 24 hours. The PTH level 
was low (0.6pmol/l, normal 1.1-6.4pmol/l) and the vitamin D level was 52nmol/l (normal 
>50 nmol/l, 25-50 nmol/l ‘insufficient’, <25 nmol/l ‘deficient’) and hence not suggestive 
of vitamin D toxicity.  The 1,25(OH)D level was low-normal at 30pmol/l (normal 20-120 
pmol/l) in keeping with a low PTH. 
Given the patients’ age and the severity of his hypercalcaemia, malignancy was 
considered to be the most likely underlying cause although there were no specific 
pointers towards a malignant focus. A blood film was normal as were plain films of 
his chest and abdomen.  Further imaging and a bone marrow biopsy to exclude 
malignancy required a general anaesthetic.  More focused treatment was therefore 
instituted as a matter of relative urgency to try and reduce calcium levels pre-
anaesthesia.   
COMMENT – Ongoing management of hypercalcaemia 
Less acute management of hypercalcaemia will focus on treating the underlying cause.  
Management and investigation typically run together.  Sometimes, as in this case, more 
definitive treatment may be required to permit further investigation. 
1-  Calcitonin  
Calcitonin is an endogenous polypeptide that directly opposes many of the effects of PTH, 
though its true physiological role in humans is unclear.  Calcitonin mainly inhibits osteoclastic 
activity, but also inhibits intestinal and renal tubule calcium reabsorption.  Therapeutically 
administered calcitonin is derived from the polypeptide found in salmon, salcatonin, which is 
more biologically active[7].  Calcitonin is almost exclusively metabolised by the kidneys, so 
may accumulate in renal impairment, though this does not seem to be a mechanism that 
contributes to hypercalcaemia in renal disease.  Administration is by intravenous infusion, by 
subcutaneous/intramuscular injection or intranasally (the latter for more chronic use).  
Adverse effects of calcitonin administration include nausea, flushing, paraesthesia, and local 
inflammation at the site of administration.  These adverse effects are common, affecting 
approximately 20% of patients. 
2- Bisphosphonates 
Bisphosphonates, such as pamidronate, bind to calcium.   Approximately 50% of the drug is 
then excreted by the kidney and the remainder is absorbed into bone.  Normal bone 
homeostasis is disrupted as bisphosphonates trigger apoptosis of  osteoclasts.  [8].  
Bisphosphonates will reduce calcium levels within 24 hours and their enduring effect means 
that some patients may then become hypocalcaemic which in turn may require treatment.  
Bisphosphonates should be used with caution in renal impairment and re-hydration is 
essential prior to commencing therapy.  Reports of renal damage are attributed to rapid 
infusion of older bisphosphonate agents.  Adverse effects include an acute phase reaction 
on first administration with pyrexia, myalgia, elevation of inflammatory markers, and 
lymphopenia.  Gastro-intestinal upset and bone pain may also occur although   paediatric 
patients appear less susceptible to adverse effects than adults. Hypocalcaemia post-
administration can be particularly troublesome in patients who have a suboptimal vitamin D 
status.   
3- Oral steroids e.g. prednisolone 
The mechanism whereby glucocorticoids reduce calcium concentrations is complex but a 
key action is the suppression of 25(OH)D activation to 1,25(OH)D. Steroids are frequently 
used in the management of malignancy because of their toxic effect on leukaemia cells. It is 
therefore imperative that malignancy has been excluded before steroid is administered as a 
treatment for hypercalcaemia. Bone marrow aspiration may be required before steroid is 
administered.  
Steroids also have a role in other conditions where there is excessive activation of vitamin D, 
such as granulomatous diseases or subcutaneous fat necrosis.  Again, the mechanism is via 
reduction in 1,25(OH)D generation. 
4 – Ketaconazole 
Ketoconazole inhibits multiple enzymes, including the enzyme 1-alpha hydroxylase. It has 
therefore been used for the treatment of infantile idiopathic hypercalcaemia[9], 
hyperparathyroidism, sarcoidosis, and other granulomatous causes of hypercalcaemia.  The 
adverse effects of ketoconazole include transaminitis, renal impairment, with hepatic 
impairment or failure in rarer cases.  This side-effect profile limits its’ value in the 
management of hypercalcaemia. 
 
One of the above management strategies will frequently be successful in reducing 
serum calcium to an acceptable level.   In Davids’ case the step-wise administration of 
fluid, calcitonin, then oral prednisolone, and finally a single dose of pamidronate 
(1mg/kg) was successful in restoring serum calcium to normal. A step-wise approach 
is usually appropriate when treating hypercalcaemia although the interval between 
treatments was relatively short in David’s case because of the severity of the 
hypercalcaemia. The reduction in serum calcium was associated with a marked 
improvement in his clinical condition.   
COMMENT: Differential diagnosis of hypercalcaemia – Altered BONE turnover 
Hypercalcaemia may reflect abnormal bone formation or abnormal bone breakdown. 
Abnormal bone turnover is a feature of immobility, abnormal muscle function and 
hypophosphatasia. The patient was not immobile and hypophosphatasia was excluded on 
the basis of patient age and a normal alkaline phosphatase at presentation.  It was 
imperative to rule out the most significant cause of abnormal calcium release from bone in 
the presence of a low PTH – malignancy. 
Hypercalcaemia is reported to complicate less than 1% of paediatric malignancies[10], but is 
far commoner in adult malignancy[11].  Mechanisms include: 
 Destruction of the bony skeleton by an actively osteolytic lesion.   
 Humoral factors produced by malignant cells promoting bone resorption - TNF-α, IL-
1, IL-6, and 1,25(OH)D 
 Excess PTHrP - The commonest factor associated with hypercalcaemia is 
parathyroid hormone-related peptide (PTHrP)[12].  PTHrP has equivalent biological 
activity to PTH and increases serum calcium through its effects on bone [promoting 
release], the kidney [reduced filtration], and indirectly on the gut [via an increase in 
activated vitamin D which increases calcium absorption].  Production of PTHrP in this 
setting is dysregulated and hypercalcaemia results. 
 
A bone marrow trephine did not demonstrate any evidence of malignancy and David 
was subsequently found to have normal PTHrP concentrations (<1pmol/l, normal 
<1.8pmol/l) A wrist radiograph was normal.  David underwent a whole body 
Technetium99 scan, alongside single positron emission computed tomography 
(SPECT) of his chest and abdomen.  Isotope uptake by the skeleton was normal apart 
from a mild diffusely increased uptake in his left ankle, but a marked increase in 
uptake over what would typically be expected in his stomach, lungs, and kidneys, 
attributed to his hypercalcaemia (Figure 2).  A plain film of the left foot demonstrated 
two minute cortical lucencies in the distal fibular metaphysis, felt to be of no 
pathological significance.   
COMMENT – Imaging 
The extensive imaging that David received was partly motivated by the strong clinical belief 
that malignancy was the most likely cause of his hypercalcaemia.   
The increased uptake on the Technetium scan in the stomach, lungs, and kidneys, is felt to 
represent transient calcium deposition within those tissues, as a result of the significant 
hypercalcaemia.  This then leads to a ‘positive’ finding as extra-osseous uptake occurs[13].    
 
David subsequently developed hypocalcaemia (a well-recognised consequence of 
bisphosphonate therapy) three days after the pamidronate, and required oral calcium 
supplementation and optimaisation of his vitamin D status.  Importantly, in the 
presence of hypocalcaemia, his urinary calcium excretion diminished to undetectable 
levels, confirming that renal filtration of calcium was normal.  Abdominal 
ultrasonography demonstrated bilaterally large (>75th centile) echogenic kidneys with 
reduced (though preserved) corticomedullary differentiation. No nephrocalcinosis 
was seen.  There was splenomegaly (8.2cm splenic length) but normal liver, 
gallbladder, and pancreas.   
COMMENT: Differential diagnosis of hypercalcaemia – KIDNEY excretion 
An important observation was that PTH concentrations were abnormally low though not 
totally suppressed. Normal PTH levels in the context of hypercalcaemia should make one 
consider calcium sensing receptor (CaSR) and related defects which can result in an altered 
calcium ‘set-point’[14,].  Calcium sensing receptors are present on the parathyroid gland, but 
also the kidney, which regulates calcium excretion (as discussed earlier).  If the kidney 
cannot detect urinary calcium, there is inappropriate reabsorption, leading to 
hypercalcaemia.  Disorders of the CaSR may present with severe hypercalcaemia in the 
neonatal period (Neonatal severe hyperparathyroidism, typically associated with 2 abnormal 
CaSR alleles) or with asymptomatic hypercalcaemia in childhood (typically associated with 
one abnormal CaSR allele)[15]. The latter abnormality is called familial hypocalciuric 
hypercalcaemia (FHH) and asymptomatic hypercalcaemia will frequently be found in one of 
the parents.  It is relatively unusual for the hypercalcaemia of FHH to be severe, and the vast 
majority of cases are asymptomatic.  The elevated urinary calcium:creatinine ratio at 
presentation also argues against a CaSR defect in David’s case. 
Excessive PTH or Vitamin D may lead to over-resorption of bone and greater serum calcium 
levels than can readily be excreted by the kidney.  In these situations, urinary calcium 
excretion is appropriately high in an attempt to normalise serum calcium.  Chronic 
hypercalcaemia will often lead to nephrocalcinosis, as the hypercalcuria predisposes to 
calculus formation.  In contrast, acute hypercalcaemia may not give sufficient time for 
precipitation. The absence of nephrocalcinosis on ultrasound in David’s case was an 
important observation because it indicated that the development of hypercalcaemia was an 
acute process.   
Investigations had thus excluded excessive GUT absorption and malignancy resulting 
in calcium release from BONE and had indicated apparently normal KIDNEY 
excretion.  The other cause of excessive GUT absorption is endogenous generation of 
active vitamin D metabolites which may result from infection and in particular 
granulomatous disease.  During the course of his admission David had a raised C-
reactive protein, initially 31mg/l, which increased to 71 mg/l and then normalised. He 
had no obvious infective contacts for tuberculosis, no history of recent foreign travel 
and no regular contact with cats.  Serum angiotensin-converting enzyme (ACE) was 
initially elevated (80U/l, normal 8-52U/l) but subsequently normalised (51U/l).   
Rheumatoid Factor was very mildly elevated (21IU/ml, normal 0-19IU/ml) but all other 
immunological investigations including complement studies, EBV and CMV serology, 
and Quantiferon-GOLD were normal.   
COMMENT: Differential diagnosis of hypercalcaemia – Granulomatous disease 
Granuloma are caused by persistence of macrophage activation either through an inability to 
clear the initial source (e.g. intracellular bacteria, foreign material or inefficient microbial 
killing in chronic granulomatous disease), or an abnormality in the processes that ‘switch off’ 
the macrophage.    
This on-going activation of T-cells and macrophages within the granuloma leads to 
endogenous expression of 1,25α-hydroxylase and excessive endogenous activated vitamin 
D (1,25(OH)D)[16].  This has exactly the same effect on GUT as excessive exogenous 
vitamin D, as discussed earlier.   
Other mycobacteria may also lead to granuloma formation.  Bartonella henselae, the 
causative organism for cat scratch fever, is typically associated with a history of superficial 
injury from a newly acquired kitten, with granuloma formation localised to the draining lymph 
nodes of the injury.  Other conditions commonly predisposing to granuloma include 
cryptococcosis, leprosy, and histoplasmosis.   
Another important, though rare, differential in the paediatric population is sarcoidosis[17].  
Granulomata form in response to an unknown trigger (still a focus of research).  Paediatric 
presentation tends to be delayed, due to its rarity, and has obvious lifelong implications.   
The presence of hilar lymphadenopathy would be characteristic, as is elevation of serum 
ACE.  Rheumatoid arthritis may also present with granulomata. 
 
None of the features in David’s history and examination were suggestive of an 
infective cause, nor did any of his extensive imaging demonstrate any visible 
granuloma.  The borderline rheumatoid factor, and initial elevation of serum ACE 
might suggest an abnormality of macrophage function, but the normalisation of all 
parameters suggested that this was not the case.    
In the absence of a specific cause David underwent an MRI of his head, spine, chest, 
abdomen, and pelvis, looking for evidence of unrecognised foci of granulomatous 
disease or malignancy but no abnormality was identified. 
By this point recognised causes of acute hypercalcaemia in childhood had been 
excluded, and we considered whether he had an atypical presentation of a neonatal 
disorder. 
COMMENT: Infantile Hypercalcaemia 
The differential diagnosis of neonatal hypercalcaemia is broad (Table 3) and in David’s case 
many of the neonatal diagnoses, such as hypophosphatasia, could be excluded on the basis 
of history or age alone. The hypercalcaemia associated with Williams syndrome may 
occasionally persist into early childhood but David did not have the associated clinical 
features. 
More recently, mutations within CYP24A1 (24-hydroxylase) which inactivates vitamin D have 
been identified as a cause of infant hypercalcaemia[5].  Though most affected patients 
develop hypercalcaemia and become symptomatic in infancy, mutational analysis of families 
has identified apparently asymptomatic older siblings. Screening for CYP24A1 mutations is 
slowly entering the investigative protocol for hypercalcaemia. The acute onset of David’s 
hypercalcaemia argues against this diagnosis, as do the normal 1,25(OH)D levels and the 
fact that his hypercalcaemia resolved and has not recurred. 
Table 3 
 
Important causes of hypercalcaemia according to age 
 
 
 
PTH 
        Infancy       Childhood 
 
 
Normal or 
raised 
 
 Neonatal severe 
hyperparathyroidism (calcium-
sensing receptor defect) 
 Calcium sensing receptor defect 
(FHH) 
 Hyperparathyroidism 
 
Low 
 Williams syndrome 
 Vitamin D excess 
 Hypophosphatasia 
 Mutations within the gene 
coding for this enzyme, 
CYP24A1 
 Idiopathic hypercalcaemia of 
infancy 
 
 Malignancy e.g. lymphoma, 
leukaemia 
 Vitamin D excess 
 Granulomatous disease 
 Thyrotoxicosis 
 
. 
 
David’s calcium rose to low normal levels with supplementation and his PTH 
normalised. Having effectively excluded malignancy and granulomatous diseases we 
opted to monitor his progress in the out-patient setting.  Vitamin D levels fell to 
21nmol/l four days post-admission, then increased to normal values (71nmol/l) 
following supplementation.   
No acute cause was identified and there has been no recurrence of either symptoms 
or hypercalcaemia.  A repeat renal ultrasound demonstrated bilateral normal-sized 
kidneys.  David was reviewed one month post-presentation at which point calcium 
levels were normal.  He re-presented eight weeks later with conjunctivitis and 
lymphadenopathy but calcium levels were normal and this was felt to be intercurrent 
infection and quickly settled.  David remains well with normal serum calcium six 
months following presentation and has been discharged from our service but with on-
going follow-up with his local paediatrician.  It is interesting to reflect on the fact that 
an underlying diagnosis may not be found in up to 15% of adults with 
hypercalcaemia[18] . 
COMMENT: Summary  
Hypercalcaemia may reflect excessive gut absorption, abnormal bone turnover or altered 
renal handling. The presentation of acute, profound hypercalcaemia in a previously well child 
should raise the possibility of an underlying malignancy. Measuring PTH concentrations, 
Vitamin D (25(OH)D) and, in selected cases,  1,25(OH)D, is of great importance when 
attempting to arrive at a diagnosis. This case highlights the fact that a definitive explanation 
for a clinical problem is not always identified and managing uncertainty remains a regular 
component of paediatric practice.    
  
MCQs 
1) Renal excretion of calcium: 
A) Is regulated by CaSR on the parathyroid 
B) Is independent of sodium handling 
C) Is elevated in FHH 
D) Is associated with nephrocalcinosis in acute hypercalcaemia 
E) May be increased through the administration of IV fluids 
2) Key considerations in hypercalcaemia management are as follows: 
A) Loop diuretics should be considered at an early stage. 
B) It is vital to correct hypercalcaemia before investigations are performed  
C) Oral glucocorticoids are a useful first line treatment in haematological malignancies 
D) Bisphosphonates may cause hypocalcaemia 
E) Avoid hyperhydration if creatinine levels are raised 
3) Granulomatous disease 
A) Occurs when macrophages cannot be activated 
B) Causes hypercalcaemia through an effect on vitamin D metabolism 
C) Is exclusively infectious in paediatric populations 
D) Is associated with an elevated PTH concentration  
E) Is characterised by a low serum ACE 
4) Hypercalcaemia 
A) Caused by inherited conditions invariably presents within the 1st year of life 
B) May cause a compensatory hyperkalaemia 
C) Will normally trigger a rise in alkaline phosphatase 
D) May result from ingestion of vitamin D tablets 
E) Always requires treatment 
5) Mechanisms resulting in the hypercalcaemia of malignancy include: 
A) Reduced activity of CYP24A1  
B) Over-production of PTH by bone marrow stem cells 
C) Excessive breakdown of bone by osteoclast activation 
D) Impaired calcitonin production 
E) Cytokine production by bony metastases 
Correct answers 
1 E 
2 D 
3 B 
4 D 
5 C E 
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